Information  X 
Enter a valid email address

Sensyne Health PLC (SENS)

  Print      Mail a friend

Wednesday 30 October, 2019

Sensyne Health PLC

Result of AGM

RNS Number : 6740R
Sensyne Health PLC
30 October 2019
 

 

 

Result of AGM

 

Oxford, UK; 30 October 2019: Sensyne Health plc (LSE: SENS) ("Company"), the British clinical AI technology company, announces that all resolutions put to its Annual General Meeting (the "AGM") held today were passed. Resolution 10 was withdrawn by the Company following the decision of Charles Swingland not to seek re-election as a Director at the AGM.

 

For information, full details of the votes received were as follows:

 

Resolution Number

For

Against

Withheld

Total Vote

No. of Votes

%

No. of Votes

%

No. of Votes

No. of Votes

1. Receive the Annual report and accounts for the Company

83,669,303

100.00

250

0.00

7,300,000

83,669,553

2. Approve the Directors' Remuneration Report

59,657,635

71.30

24,011,918

28.70

7,300,000

83,669,553

3. Re-elect Lord (Paul) Drayson as a Director

49,183,591

100.00

2,000

0.00

15,270

49,185,591

4. Re-elect Andrew Gilbert as a Director

75,420,438

90.16

8,233,865

9.84

7,315,250

83,654,303

5. Re-elect Dr Vishal Gulati as a Director

83,654,303

100.00

0

0.00

7,315,250

83,654,303

6. Re-elect Mary Hardy as a Director

83,654,303

100.00

0

0.00

7,315,250

83,654,303

7. Re-elect Lorimer Headley as a Director

83,654,303

100.00

0

0.00

7,315,250

83,654,303

8. Re-elect Dr Annalisa Jenkins as a Director

90,954,303

100.00

0

0.00

15,250

90,954,303

9. Re-elect Sir Bruce Keogh as a Director

83,654,303

100.00

0

0.00

7,315,250

83,654,303

10. Re-elect Charles Swingland as a Director

RESOLUTION WITHDRAWN

11. Elect Professor Lionel Tarassenko as a Director

83,497,695

99.81

156,608

0.19

7,315,250

83,654,303

12. Re-appoint PricewaterhouseCoopers LLP as auditors of the Company

83,669,303

100.00

0

0.00

7,300,250

83,669,303

13. Authorise the Audit & Risk Committee of the Company

83,669,303

100.00

0

0.00

7,300,250

83,669,303

14. Directors' authority to allot shares

80,209,253

100.00

0

0.00

10,760,300

80,209,253

15. Disapplication of pre-emption rights*

80,209,253

100.00

0

0.00

10,760,300

80,209,253

16. Disapplication of pre-emption rights Addition*

80,206,753

100.00

0

0.00

10,762,800

80,206,753

17. Authority to purchase own shares*

80,209,253

100.00

0

0.00

10,760,300

80,209,253

18. Rule 9 Waiver - Relating to Buyback Authority

25,056,044

65.18

13,384,497

34.82

10,760,320

38,440,541

19. Rule 9 Waiver - Relating to the Exercise of Options

25,053,544

65.17

13,386,997

34.83

10,760,320

38,440,541

 

Notes:    

 1.   Resolution 10 was withdrawn as Charles Swingland decided not to seek re-election as a Director at the AGM.

2.   A vote withheld is not a vote in law and is not counted in calculating votes for or against a resolution.

3.   The total number of ordinary shares in issue as at 30 October 2019 was 128,571,514 (128,571,514 with voting rights).

* Special Resolution requiring a 75% majority.

 

The Board notes that more than 20% of shareholders voted against resolution 2 on approving the Directors' Remuneration Report. As noted in the Company's announcement of 22 October 2019 headed Remuneration Policy and Corporate Governance Update, a number of actions have already been implemented addressing the issue of remuneration. The Company has withdrawn the remuneration policy in relation to the CEO for the period from 1st May 2019 to 30th April 2020 and the Remuneration Committee will also undertake discussions with shareholders to determine a new Remuneration Policy for the CEO applicable to the period from 1st May 2019 until 30th April 2020 that has their support.

 

-ENDS-

 

For more information please contact:

 

Sensyne Health (www.sensynehealth.com)

+44 (0) 330 058 1845

Lord (Paul) Drayson, Chief Executive Officer


Lorimer Headley, Chief Financial Officer




Peel Hunt LLP (Nominated Adviser and Joint Broker)

+ 44 (0) 20 7418 8900

Dr Christopher Golden


James Steel


Oliver Jackson


 

 


Liberum (Joint Broker)

+ 44 (0) 20 3100 2000

Bidhi Bhoma


Euan Brown




Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott


Sukaina Virji


Melissa Gardiner


[email protected]


 

 

About Sensyne Health

Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company's access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care's 'Initial Code of Conduct for data-driven health and care technology.

 

Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

For more information, please visit: www.sensynehealth.com

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RAGCKKDBQBDDAKN

a d v e r t i s e m e n t